Andrew D. Cherniack, Ph.D. - Publications

Affiliations: 
Broad Institute, Cambridge, MA, United States 
Area:
Genomics, Molecular Biology

117 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, ... ... Cherniack AD, et al. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nature Medicine. PMID 35739269 DOI: 10.1038/s41591-022-01856-6  0.752
2022 Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, ... ... Cherniack AD, et al. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. Jama Oncology. PMID 35708671 DOI: 10.1001/jamaoncol.2022.1981  0.762
2021 Cleary JM, Raghavan S, Wu Q, Li YY, Spurr LF, Gupta HV, Rubinson DA, Fetter IJ, Hornick JL, Nowak JA, Siravegna G, Goyal L, Shi L, Brais LK, Loftus M, ... ... Cherniack AD, et al. FGFR2 Extracellular Domain In-Frame Deletions are Therapeutically Targetable Genomic Alterations that Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discovery. PMID 33926920 DOI: 10.1158/2159-8290.CD-20-1669  0.774
2021 Alessi JV, Ricciuti B, Spurr LF, Gupta H, Li YY, Glass C, Nishino M, Cherniack AD, Lindsay J, Sharma B, Felt KD, Rodig SJ, Cheng ML, Sholl LM, Awad MM. SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33845210 DOI: 10.1016/j.jtho.2021.03.024  0.775
2020 Braun DA, Hou Y, Bakouny Z, Ficial M, Sant' Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine. PMID 32472114 DOI: 10.1038/S41591-020-0839-Y  0.339
2020 Oak N, Cherniack AD, Mashl RJ, Hirsch FR, Ding L, Beroukhim R, Gümüş ZH, Plon SE, Huang KL. Ancestry-specific predisposing germline variants in cancer. Genome Medicine. 12: 51. PMID 32471518 DOI: 10.1186/S13073-020-00744-3  0.314
2020 Nichols CA, Gibson WJ, Brown MS, Kosmicki JA, Busanovich JP, Wei H, Urbanski LM, Curimjee N, Berger AC, Gao GF, Cherniack AD, Dhe-Paganon S, Paolella BR, Beroukhim R. Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nature Communications. 11: 2517. PMID 32433464 DOI: 10.1038/S41467-020-16399-Y  0.35
2020 Carrot-Zhang J, Chambwe N, Damrauer JS, Knijnenburg TA, Robertson AG, Yau C, Zhou W, Berger AC, Huang KL, Newberg JY, Mashl RJ, Romanel A, Sayaman RW, Demichelis F, Felau I, ... ... Cherniack AD, et al. Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell. 37: 639-654.e6. PMID 32396860 DOI: 10.1016/J.Ccell.2020.04.012  0.392
2020 Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, Umeton R, Cherniack AD, Nishino M, Sholl LM, Shapiro GI, Awad MM, Cheng ML. Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32332016 DOI: 10.1158/1078-0432.Ccr-19-3529  0.388
2020 Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ferrer-Luna R, Ramkissoon SH, Dubois F, ... ... Cherniack AD, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 580: 517-523. PMID 32322066 DOI: 10.1038/S41586-020-2209-9  0.366
2020 Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, Spurr LF, Li YY, Li T, Flaifel A, Steinharter JA, ... ... Cherniack AD, et al. Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors. Cancer Immunology Research. PMID 32321774 DOI: 10.1158/2326-6066.Cir-19-0866  0.389
2020 Lamberti G, Spurr LF, Li Y, Ricciuti B, Recondo G, Umeton R, Nishino M, Sholl LM, Meyerson ML, Cherniack AD, Awad MM. Clinicopathological and genomic correlates of Programmed Cell Death Ligand 1 (PD-L1) expression in nonsquamous non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32171752 DOI: 10.1016/J.Annonc.2020.02.017  0.325
2020 Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, Lo YC, Li YY, Lamberti G, Nguyen T, Milan MSD, Venkatraman D, Umeton R, Paweletz CP, Albayrak A, ... Cherniack AD, et al. Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32034073 DOI: 10.1158/1078-0432.Ccr-19-3608  0.323
2020 Wu X, Schnitzler GR, Gao GF, Diamond B, Baker AR, Kaplan B, Williamson K, Westlake L, Lorrey S, Lewis TA, Garvie CW, Lange M, Hayat S, Seidel H, Doench J, ... Cherniack AD, et al. Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12. The Journal of Biological Chemistry. PMID 32005668 DOI: 10.1074/Jbc.Ra119.011191  0.381
2020 Cleary JM, Raghavan S, Li YY, Spurr L, Wu Q, Shi L, Brais LK, Odhiambo Z, Goyal L, Patel AK, Shinagare AB, Clancy TE, Shapiro G, Cerami E, Sellers WR, ... ... Cherniack AD, et al. Therapeutic targeting of extracellular FGFR2 activating deletions in intrahepatic cholangiocarcinoma. Journal of Clinical Oncology. 38: 567-567. DOI: 10.1200/Jco.2020.38.4_Suppl.567  0.384
2020 Ricciuti B, Arbour KC, Lin JJ, Vokes N, Hoojghan AV, Li YY, Cherniack AD, Recondo G, Lamberti G, Venkatraman D, Rizvi H, Egger JV, Plodkowski AJ, Khosrowjerdi S, Digumarthy SR, et al. Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E15113  0.347
2020 Kabraji SK, Spurr LF, Hughes ME, Li YY, Leone JP, Garrido-Castro AC, Barroso-Sousa R, Files J, Kirkner G, Johnson BE, Winer EP, Cherniack AD, Lin NU. Genomic profiling of breast cancer brain metastases reveals targetable alterations. Journal of Clinical Oncology. 38: 2525-2525. DOI: 10.1200/Jco.2020.38.15_Suppl.2525  0.318
2020 Taylor AM, Jain S, Shih J, Cherniack AD, Beroukhim R, Meyerson M. Abstract A44: Functional models of chromosome arm-level aneuploidies in cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-A44  0.333
2020 Neggers JE, Paolella BR, Asfaw A, Rothberg MV, Skipper TA, Kalekar RL, Krill-Burger JM, Hong AL, Kugener G, Kalfon J, Yang A, Yuan C, Dumont N, Gonzalez A, Abdusamad M, ... ... Cherniack AD, et al. Abstract LB-053: VPS4A is a synthetic lethal target in VPS4B-deficient cancers due to co-deletion with SMAD4 Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Lb-053  0.407
2020 Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu B, Bohrson CL, Cortes-Ciriano I, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ramkissoon SH, Dubois F, Bellamy C, Currimjee N, ... ... Cherniack A, et al. Abstract 5705: Mechanisms and therapeutic implications of hypermutation in gliomas Cancer Research. 80: 5705-5705. DOI: 10.1158/1538-7445.Am2020-5705  0.393
2020 Spurr LF, Lamberti G, Li YY, Ricciuti B, Recondo G, Umeton R, Sholl LM, Meyerson ML, Cherniack AD, Awad MM. Abstract 5668: Genomic correlates of PD-L1 expression are associated with response to immunotherapy in non-small cell lung cancer Cancer Research. 80: 5668-5668. DOI: 10.1158/1538-7445.Am2020-5668  0.326
2019 Chen H, Carrot-Zhang J, Zhao Y, Hu H, Freeman SS, Yu S, Ha G, Taylor AM, Berger AC, Westlake L, Zheng Y, Zhang J, Ramachandran A, Zheng Q, Pan Y, ... ... Cherniack AD, et al. Genomic and immune profiling of pre-invasive lung adenocarcinoma. Nature Communications. 10: 5472. PMID 31784532 DOI: 10.1038/S41467-019-13460-3  0.359
2019 Stover EH, Baco MB, Cohen O, Li YY, Christie EL, Bagul M, Goodale A, Lee Y, Pantel S, Rees MG, Wei G, Presser AG, Gelbard MK, Zhang W, Zervantonakis IK, ... ... Cherniack AD, et al. Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer. Molecular Cancer Research : McR. PMID 31462500 DOI: 10.1158/1541-7786.Mcr-18-1243  0.313
2019 Gao GF, Parker JS, Reynolds SM, Silva TC, Wang LB, Zhou W, Akbani R, Bailey M, Balu S, Berman BP, Brooks D, Chen H, Cherniack AD, Demchok JA, Ding L, et al. Before and After: Comparison of Legacy and Harmonized TCGA Genomic Data Commons' Data. Cell Systems. 9: 24-34.e10. PMID 31344359 DOI: 10.1016/J.Cels.2019.06.006  0.311
2019 Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, ... ... Cherniack AD, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. PMID 31068700 DOI: 10.1038/S41586-019-1186-3  0.347
2019 Greulich H, Cherniack AD. Genetic clues can be used to predict whether early-stage cancer will form an invasive tumour. Nature. 566: 336-337. PMID 30778180 DOI: 10.1038/D41586-019-00567-2  0.329
2019 Smithy JW, Hwang DH, Li YY, Spurr L, Cherniack AD, Sholl LM, Awad MM. Changes in tumor mutational burden in serially biopsied non-small cell lung cancer. Journal of Clinical Oncology. 37: e14286-e14286. DOI: 10.1200/Jco.2019.37.15_Suppl.E14286  0.374
2019 Garrido-Castro AC, Spurr L, Hughes ME, Li YY, Cherniack AD, Bychkovsky BL, Barroso-Sousa R, Lascio SD, Files J, Kumari P, Cerami E, Krop IE, MacConaill LE, Lindeman NI, Rollins BJ, et al. Genomic landscape of de novo stage IV breast cancer. Journal of Clinical Oncology. 37: 1022-1022. DOI: 10.1200/Jco.2019.37.15_Suppl.1022  0.31
2019 Stover EH, Baco MB, Cohen O, Li Y, Christie E, Bagul M, Goodale A, Lee Y, Pantel S, Rees M, Wei G, Presser A, Zervantonakis I, Bhola P, Ryan J, ... ... Cherniack A, et al. Abstract AP14: POOLED GENOMIC SCREENS IDENTIFY ANTI-APOPTOTIC GENES AS MEDIATORS OF CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Ap14  0.323
2019 Garrido-Castro A, Hughes M, Cherniack A, Barroso-Sousa R, Bychkovsky B, Lascio SD, Berger A, Mittendorf E, Files J, Guo H, Kumari P, Cerami E, Krop I, Wagle N, Lindeman N, et al. Abstract PD9-01: Genomic alterations associated with loss of HR expression in metastatic breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Pd9-01  0.379
2019 Touat M, Li Y, Boynton A, Spurr L, Iorgulescu B, Birzu C, Pal S, Ferrer-Luna R, Geduldig J, Bellamy C, Younan N, Baldini C, Verreault M, Guillerm E, Ammari S, ... ... Cherniack A, et al. DRES-08. CLINICAL SIGNIFICANCE OF HYPERMUTATION IN GLIOMAS Neuro-Oncology. 21: vi73-vi73. DOI: 10.1093/Neuonc/Noz175.296  0.357
2019 Touat M, Li Y, Boynton A, Spurr L, Iorglescu B, Geduldig J, Birzu C, Lim Fat M, Santagata S, Coulet F, Beuvon F, Mokhtari K, Giry M, Block S, Guillerm E, ... ... Cherniack A, et al. OS9.1 Clinical significance of hypermutation in gliomas Neuro-Oncology. 21: iii18-iii18. DOI: 10.1093/Neuonc/Noz126.059  0.343
2018 Gannon HS, Zou T, Kiessling MK, Gao GF, Cai D, Choi PS, Ivan AP, Buchumenski I, Berger AC, Goldstein JT, Cherniack AD, Vazquez F, Tsherniak A, Levanon EY, Hahn WC, et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nature Communications. 9: 5450. PMID 30575730 DOI: 10.1038/S41467-018-07824-4  0.389
2018 Holst F, Werner HMJ, Mjøs S, Hoivik EA, Kusonmano K, Wik E, Berg A, Birkeland E, Gibson WJ, Halle MK, Trovik J, Cherniack AD, Kalland KH, Mills GB, Singer CF, et al. Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30442683 DOI: 10.1158/1078-0432.Ccr-18-0452  0.392
2018 Sasanuma H, Tsuda M, Morimoto S, Saha LK, Rahman MM, Kiyooka Y, Fujiike H, Cherniack AD, Itou J, Callen Moreu E, Toi M, Nakada S, Tanaka H, Tsutsui K, Yamada S, et al. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. Proceedings of the National Academy of Sciences of the United States of America. PMID 30352856 DOI: 10.1073/Pnas.1803177115  0.326
2018 Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman DI, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, ... ... Cherniack AD, et al. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discovery. PMID 30322867 DOI: 10.1158/2159-8290.Cd-18-0804  0.396
2018 Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, ... ... Cherniack AD, et al. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. Cell Systems. PMID 30268436 DOI: 10.1016/J.Cels.2018.08.010  0.336
2018 Viswanathan SR, Nogueira MF, Buss CG, Krill-Burger JM, Wawer MJ, Malolepsza E, Berger AC, Choi PS, Shih J, Taylor AM, Tanenbaum B, Pedamallu CS, Cherniack AD, Tamayo P, Strathdee CA, et al. Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nature Genetics. PMID 29955178 DOI: 10.1038/S41588-018-0155-3  0.365
2018 Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sánchez-Vega F, Pluta J, Pyle LC, Mehra R, ... ... Cherniack AD, et al. Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Reports. 23: 3392-3406. PMID 29898407 DOI: 10.1016/J.Celrep.2018.05.039  0.362
2018 Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, ... ... Cherniack AD, et al. The Immune Landscape of Cancer. Immunity. PMID 29628290 DOI: 10.1016/J.Immuni.2018.03.023  0.364
2018 Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 173: 400-416.e11. PMID 29625055 DOI: 10.1016/J.Cell.2018.02.052  0.354
2018 Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlahan KE, Jayasinghe R, et al. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell. 173: 355-370.e14. PMID 29625052 DOI: 10.1016/J.Cell.2018.03.039  0.375
2018 Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, ... ... Cherniack AD, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 173: 321-337.e10. PMID 29625050 DOI: 10.1016/J.Cell.2018.03.035  0.407
2018 Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, ... ... Cherniack AD, et al. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell. 173: 305-320.e10. PMID 29625049 DOI: 10.1016/J.Cell.2018.03.033  0.387
2018 Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell. 173: 291-304.e6. PMID 29625048 DOI: 10.1016/J.Cell.2018.03.022  0.338
2018 Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, et al. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell. PMID 29622466 DOI: 10.1016/J.Ccell.2018.03.010  0.386
2018 Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, ... ... Cherniack AD, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. PMID 29622464 DOI: 10.1016/J.Ccell.2018.03.014  0.386
2018 Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ, Cherniack AD, Beroukhim R, Meyerson M. Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. PMID 29622463 DOI: 10.1016/J.Ccell.2018.03.007  0.37
2018 Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Miller C, et al. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports. 23: 239-254.e6. PMID 29617664 DOI: 10.1016/J.Celrep.2018.03.076  0.394
2018 Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, et al. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports. 23: 194-212.e6. PMID 29617660 DOI: 10.1016/J.Celrep.2018.03.063  0.356
2018 Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N, Sanchez Y, Greene CS. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Reports. 23: 172-180.e3. PMID 29617658 DOI: 10.1016/J.Celrep.2018.03.046  0.364
2018 Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, et al. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems. 6: 282-300.e2. PMID 29596783 DOI: 10.1016/J.Cels.2018.03.003  0.41
2018 Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, ... ... Cherniack AD, et al. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell. 33: 244-258.e10. PMID 29438696 DOI: 10.1016/J.Ccell.2018.01.003  0.354
2018 Liu J, Lichtenberg T, Hoadley K, Cherniack A, Poisson L, Kovatich A, Benz C, Thorsson V, Shriver C, Hu H. Abstract P3-16-01: Using the new pan-cancer clinical data resource (TCGA-CDR) to identify breast cancer genomic correlates associating with different survival outcome endpoints Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-16-01  0.348
2018 Korkut A, Zaidi S, Kanchi R, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Schultz A, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, ... ... Cherniack AD, et al. Abstract 3413: A pan-cancer atlas of genomic, epigenomic and transcriptomic alterations in the TGF-β pathway Cancer Research. 78: 3413-3413. DOI: 10.1158/1538-7445.Am2018-3413  0.38
2018 Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La K, Dimitriadoy S, Liu DL, Kantheti HS, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, ... ... Cherniack AD, et al. Abstract 3302: The molecular landscape of oncogenic signaling pathways in The Cancer Genome Atlas Cancer Research. 78: 3302-3302. DOI: 10.1158/1538-7445.Am2018-3302  0.418
2018 Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Hu H. Abstract 3287: An integrated TCGA pan-cancer clinical data resource to drive high quality survival outcome analytics Cancer Research. 78: 3287-3287. DOI: 10.1158/1538-7445.Am2018-3287  0.356
2018 Nichols CA, Paolella BR, Gibson WJ, Brown MS, Urbanski LM, Kosmicki JA, Busanovich JP, Berger AC, Gao GF, Cherniack AD, Beroukhim R. Abstract 3003: Loss of heterozygosity of essential genes represents a novel class of cancer vulnerabilities Cancer Research. 78: 3003-3003. DOI: 10.1158/1538-7445.Am2018-3003  0.352
2018 Taylor AM, Zhang X, Shih J, Ha G, Gao GF, Berger AC, Cherniack AD, Beroukhim R, Meyerson M. Abstract 3002: Genome engineering approaches to generate models of chromosome arm-level cancer aneuploidy Cancer Research. 78: 3002-3002. DOI: 10.1158/1538-7445.Am2018-3002  0.319
2017 Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. PMID 28988769 DOI: 10.1016/J.Cell.2017.09.007  0.341
2017 Zhang X, Choi PS, Francis JM, Gao GF, Campbell JD, Ramachandran A, Mitsuishi Y, Ha G, Shih J, Vazquez F, Tsherniak A, Taylor AM, Zhou J, Wu Z, Berger AC, ... ... Cherniack AD, et al. Somatic super-enhancer duplications and hotspot mutations lead to oncogenic activation of the KLF5 transcription factor. Cancer Discovery. PMID 28963353 DOI: 10.1158/2159-8290.Cd-17-0532  0.421
2017 Goldstein JT, Berger AC, Shih J, Duke FF, Furst L, Kwiatkowski DJ, Cherniack AD, Meyerson M, Strathdee CA. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Research. PMID 28923856 DOI: 10.1158/0008-5472.Can-17-1701  0.393
2017 Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, ... ... Cherniack AD, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 32: 204-220.e15. PMID 28810145 DOI: 10.1016/J.Ccell.2017.07.003  0.327
2017 Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, ... ... Cherniack AD, et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports. 19: 2878-2880. PMID 28658632 DOI: 10.1016/J.Celrep.2017.06.008  0.306
2017 Martin KR, Zhou W, Bowman MJ, Shih J, Au KS, Dittenhafer-Reed KE, Sisson KA, Koeman J, Weisenberger DJ, Cottingham SL, DeRoos ST, Devinsky O, Winn ME, Cherniack AD, Shen H, et al. The genomic landscape of tuberous sclerosis complex. Nature Communications. 8: 15816. PMID 28643795 DOI: 10.1038/Ncomms15816  0.353
2017 Cho SY, Park JW, Liu Y, Park YS, Kim JH, Yang H, Um H, Ko WR, Lee BI, Kwon SY, Ryu SW, Kwon CH, Park DY, Lee JH, Lee SI, ... ... Cherniack AD, et al. Sporadic Early-onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations but Low Frequency of Somatic RHOA Mutations Compared with Late-onset Cancers. Gastroenterology. PMID 28522256 DOI: 10.1053/J.Gastro.2017.05.012  0.304
2017 Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, Ru Y, Lichtenberg T, Sturtz LA, Shelley CS, Benz CC, et al. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. Jama Oncology. PMID 28472234 DOI: 10.1001/Jamaoncol.2017.0595  0.311
2017 Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, ... ... Cherniack AD, et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports. 18: 2780-2794. PMID 28297679 DOI: 10.1016/J.Celrep.2017.02.033  0.367
2017 Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 31: 411-423. PMID 28292439 DOI: 10.1016/J.Ccell.2017.02.010  0.396
2017 Lerner SP, Robertson G, Kim J, Cherniack A, Guo G, Akbani R, Kanchi RS, Hoadley KA, Hinoue T, Laird PW, Al-Ahmadie H, Bellmunt J, Castro M, Gordenin D, Mills GB, et al. Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas. Journal of Clinical Oncology. 35: 4500-4500. DOI: 10.1200/Jco.2017.35.15_Suppl.4500  0.371
2017 Meyers RM, Aguirre AJ, Weir BA, Vazquez F, Zhang C, Ben-David U, Cook A, Ha G, Harrington WF, Doshi M, Gill S, Xu H, Ali LD, Jiang G, Pantel S, ... ... Cherniack AD, et al. Abstract B39: Genomic copy number alterations introduce a gene-independent viability bias in CRISPR-Cas9 knock-out screens of cancer cell lines Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-B39  0.367
2017 Huo D, Hu H, Rhie S, Gamazon E, Cherniack A, Liu J, Yoshimatsu T, Pitt J, Hoadley K, Troester M, Ru Y, Lichtenberg T, Sturtz L, Shelley C, Mills G, et al. Abstract P1-05-11: Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-05-11  0.338
2016 Gibson WJ, Hoivik EA, Halle MK, Taylor-Weiner A, Cherniack AD, Berg A, Holst F, Zack TI, Werner HM, Staby KM, Rosenberg M, Stefansson IM, Kusonmano K, Chevalier A, Mauland KK, et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. PMID 27348297 DOI: 10.1038/Ng.3602  0.401
2016 Aguirre AJ, Meyers RM, Weir BA, Vazquez F, Zhang CZ, Ben-David U, Cook A, Ha G, Harrington WF, Doshi MB, Kost-Alimova M, Gill S, Xu H, Ali LD, Jiang G, ... ... Cherniack AD, et al. Genomic copy number dictates a gene-independent cell response to CRISPR-Cas9 targeting. Cancer Discovery. PMID 27260156 DOI: 10.1158/2159-8290.Cd-16-0154  0.344
2016 Holst F, Hoivik EA, Gibson WJ, Taylor-Weiner A, Schumacher SE, Asmann YW, Grossmann P, Trovik J, Necela BM, Thompson EA, Meyerson M, Beroukhim R, Salvesen HB, Cherniack AD. Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Scientific Reports. 6: 25521. PMID 27160768 DOI: 10.1038/Srep25521  0.354
2016 Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, ... ... Cherniack AD, et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 164: 550-563. PMID 26824661 DOI: 10.1016/J.Cell.2015.12.028  0.337
2016 Lerner SP, Kim J, Kwiatkowski DJ, Getz G, Weinstein JN, Cherniack A, Guo G, Akbani R, Hoadley KA, Kim WY, Robertson G, Mungall AJ, Hinoue T, Laird PW, Al-Ahmadie H, et al. Comprehensive characterization of 412 muscle invasive urothelial carcinomas: Final analysis of The Cancer Genome Atlas (TCGA) project. Journal of Clinical Oncology. 34: 405-405. DOI: 10.1200/Jco.2016.34.2_Suppl.405  0.387
2016 Thompson E, Asmann Y, Su X, Ellis M, Shao J, Hu Y, White K, Cherniack A, Hoadley K, Serie D, Perez E, Perou C. Abstract S4-02: A comprehensive analysis of fusion transcripts in breast cancer reveals associations between number of fusion transcripts, copy number events, gene expression profiles, and potentially clinical outcome Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-S4-02  0.364
2016 Weinstein JN, Lerner SP, Kwiatkowski DJ, Getz G, Kim J, Al-ahmadie HA, Cherniack AD, Guo G, Akbani R, Hoadley KA, Kim WY, Robertson G, Mungall AJ, Hinoue T, Laird PW, et al. Abstract 128: Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas: final analysis of The Cancer Genome Atlas (TCGA) project Cancer Research. 76: 128-128. DOI: 10.1158/1538-7445.Am2016-128  0.426
2015 Zhang X, Choi PS, Francis JM, Imielinski M, Watanabe H, Cherniack AD, Meyerson M. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nature Genetics. PMID 26656844 DOI: 10.1038/Ng.3470  0.404
2015 Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, ... ... Cherniack AD, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 163: 506-19. PMID 26451490 DOI: 10.1016/J.Cell.2015.09.033  0.365
2015 Murray B, Albiges L, Van Allen EM, Cherniack A, Fay AP, Meyerson M, Choueiri TK. Precision medicine approach in kidney cancer: A pan renal cell carcinoma (RCC) study across three cancer genome atlas (TCGA) datasets for clinically relevant target identification. Journal of Clinical Oncology. 33: 4564-4564. DOI: 10.1200/Jco.2015.33.15_Suppl.4564  0.39
2015 Albiges L, Murray B, Brooks A, Cherniack A, Berger A, Creighton CJ, Ricketts C, Bottaro DP, Srinivasan R, Schmidt LS, Meyerson M, Spellman P, Linehan WM, Choueiri TK. Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group. Journal of Clinical Oncology. 33: 4521-4521. DOI: 10.1200/Jco.2015.33.15_Suppl.4521  0.388
2015 Ciriello G, Gatza ML, Hoadley KA, Zhang H, Rhie SK, Bowlby R, Wilkerson MD, Kandoth C, McLellan M, Cherniack A, Laird PW, Sander C, King TA, Perou CM. Abstract S2-04: Comprehensive molecular characterization of invasive lobular breast tumors Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S2-04  0.415
2015 Weinstein JN, Kim J, Creighton CJ, Akbani R, Hoadley KA, Kim WY, Morgan MB, Hinoue T, Cherniack A, Su X, Mungall AJ, Ryan MC, Bajorin DF, Rosenberg JE, Czerniak B, et al. Abstract 2969: Progress in The Cancer Genome Atlas bladder cancer project Cancer Research. 75: 2969-2969. DOI: 10.1158/1538-7445.Am2015-2969  0.329
2015 Barthel FP, Ceccarelli M, Malta TM, Sabedot TS, Salama SR, Pagnotta SM, Murray BA, Morozova O, Newton Y, Brat DJ, Cherniack AD, Zhang H, Poisson L, Cooper L, Rabadan R, et al. GENO-06A PAN-GLIOMA CHARACTERIZATION OF GENOMIC, EPIGENOMIC AND TRANSCRIPTOMIC ACTIVITIES REVEALS NOVEL RELATIONSHIPS BETWEEN HISTOLOGICAL SUBTYPES AND MOLECULAR SIGNATURES Neuro-Oncology. 17: v92.2-v92. DOI: 10.1093/Neuonc/Nov215.06  0.368
2014 Sharifnia T, Rusu V, Piccioni F, Bagul M, Imielinski M, Cherniack AD, Pedamallu CS, Wong B, Wilson FH, Garraway LA, Altshuler D, Golub TR, Root DE, Subramanian A, Meyerson M. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 18661-6. PMID 25512530 DOI: 10.1073/Pnas.1412228112  0.363
2014 Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 26: 319-30. PMID 25155756 DOI: 10.1016/J.Ccr.2014.07.014  0.398
2014 Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 158: 929-44. PMID 25109877 DOI: 10.1016/J.Cell.2014.06.049  0.375
2014 Wik E, Trovik J, Kusonmano K, Birkeland E, Raeder MB, Pashtan I, Hoivik EA, Krakstad C, Werner HM, Holst F, Mjøs S, Halle MK, Mannelqvist M, Mauland KK, Oyan AM, ... ... Cherniack AD, et al. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 134: 599-606. PMID 24995579 DOI: 10.1016/J.Ygyno.2014.06.026  0.338
2014 Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, McConkey D, Lerner S, Morgan M, Creighton CJ, Smith C, Cherniack AD, Kim J, Pedamallu CS, Noble MS, Al-Ahmadie HA, et al. Comprehensive molecular characterization of urothelial bladder carcinoma Nature. 507: 315-322. PMID 24476821 DOI: 10.1038/Nature12965  0.413
2014 Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio L, Cibulskis K, Bertelsen B, Romero-Cordoba S, Treviño V, Vazquez-Santillan K, Guadarrama AS, Wright AA, et al. Landscape of genomic alterations in cervical carcinomas. Nature. 506: 371-5. PMID 24390348 DOI: 10.1038/Nature12881  0.325
2014 Rosenberg JE, Kim J, Cherniack A, Sougnez C, Meyerson M, Getz G, Weinstein JN, Lerner SP, Kwiatkowski DJ. Somatic genomic alterations in urothelial cancer: Results of the Cancer Genome Atlas (TCGA) bladder cancer (BC) analysis. Journal of Clinical Oncology. 32: 285-285. DOI: 10.1200/Jco.2014.32.4_Suppl.285  0.402
2014 Berger AH, Brooks AN, Imielinski M, Cherniack A, Duke F, Kaplan N, Wala J, Meyerson M. Abstract PR08:NF1,MET, andRIT1mutations are RAS-pathway driver events in lung adenocarcinoma Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-Pr08  0.391
2014 Weinstein JN, Kim J, Creighton CJ, Akbani R, Hoadley KA, Kim WY, Morgan MB, Hinoue T, Cherniack A, Su X, Mungall AJ, Ryan MC, Rosenberg JE, Bajorin DF, Czerniak B, et al. Abstract 987: Comprehensive characterization of urothelial bladder cancer: a TCGA Project update Cancer Research. 74: 987-987. DOI: 10.1158/1538-7445.Am2014-987  0.447
2014 Ojesina AI, Murray B, Bjorge L, Woie K, Krakstad C, Lichtenstein L, Pedamallu CS, Taylor-Weiner A, Freeman SS, Cherniack AD, Lawrence MS, Cibulskis K, Carter SL, Walline H, Carey TE, et al. Abstract 4692: Relationships between somatic genomic alterations, tumor stage and progression-free survival in cervical cancer Cancer Research. 74: 4692-4692. DOI: 10.1158/1538-7445.Am2014-4692  0.38
2013 Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, Wilkerson MD, Fecci PE, Butaney M, Reibel JB, Soucheray M, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discovery. 3: 1355-63. PMID 24078774 DOI: 10.1158/2159-8290.Cd-13-0310  0.348
2013 Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, Lawrence MS, Zhsng CZ, Wala J, Mermel CH, Sougnez C, Gabriel SB, Hernandez B, Shen H, Laird PW, et al. Pan-cancer patterns of somatic copy number alteration. Nature Genetics. 45: 1134-40. PMID 24071852 DOI: 10.1038/Ng.2760  0.411
2013 Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, Spear ED, Carter SL, Meyerson M, Sabatini DM. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science (New York, N.Y.). 340: 1100-6. PMID 23723238 DOI: 10.1126/Science.1232044  0.379
2013 Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 497: 67-73. PMID 23636398 DOI: 10.1038/Nature12113  0.363
2013 Pashtan IM, Neuberg DS, Beroukhim R, Salvesen HB, Cherniack A. Distinct copy number alteration patterns as prognostic of endometrial cancer outcomes. Journal of Clinical Oncology. 31: 5511-5511. DOI: 10.1200/Jco.2013.31.15_Suppl.5511  0.334
2012 Hammerman PS, Voet D, Lawrence MS, Jing R, Cibulskis K, Sivachenko A, Stojanov P, McKenna A, Lander ES, Gabriel S, Getz G, Imielinski M, Helman E, Hernandez B, Pho NH, ... ... Cherniack AD, et al. Comprehensive genomic characterization of squamous cell lung cancers Nature. 489: 519-525. PMID 22960745 DOI: 10.1038/Nature11404  0.401
2012 Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, Kovar CL, Lewis LR, Morgan MB, Newsham IF, Reid JG, Santibanez J, Shinbrot E, Trevino LR, Wu YQ, ... ... Cherniack AD, et al. Comprehensive molecular characterization of human colon and rectal cancer Nature. 487: 330-337. PMID 22810696 DOI: 10.1038/Nature11252  0.408
2012 Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton LL, Dooling DJ, Ding L, Mardis ER, Wilson RK, Ally A, Balasundaram M, Butterfield YSN, Carlsen R, ... ... Cherniack AD, et al. Comprehensive molecular portraits of human breast tumours Nature. 490: 61-70. DOI: 10.1038/Nature11412  0.373
2011 Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S, Verhaak R, Cherniack AD, Watanabe H, Dutt A, Kwon J, Chao YS, Onofrio RC, Chiang D, Yuza Y, et al. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Research. 71: 7587-96. PMID 22001862 DOI: 10.1158/0008-5472.Can-11-0821  0.36
2011 Lin W, Cao J, Liu J, Beshiri ML, Fujiwara Y, Francis J, Cherniack AD, Geisen C, Blair LP, Zou MR, Shen X, Kawamori D, Liu Z, Grisanzio C, Watanabe H, et al. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proceedings of the National Academy of Sciences of the United States of America. 108: 13379-86. PMID 21788502 DOI: 10.1073/Pnas.1110104108  0.313
2009 Klarlund JK, Cherniack AD, McMahon M, Czech MP. P-63: Activation of the Raf/Mitogen-activated protein kinase pathway is not sufficient for disassembly of Grb2/Sos or p21ras desensitization Experimental and Clinical Endocrinology & Diabetes. 104: 128-129. DOI: 10.1055/S-0029-1211606  0.729
2006 Powelka AM, Seth A, Virbasius JV, Kiskinis E, Nicoloro SM, Guilherme A, Tang X, Straubhaar J, Cherniack AD, Parker MG, Czech MP. Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes Journal of Clinical Investigation. 116: 125-136. PMID 16374519 DOI: 10.1172/Jci26040  0.737
2001 Bose A, Cherniack AD, Langille SE, Nicoloro SMC, Buxton JM, Park JG, Chawla A, Czech MP. Gα11 signaling through ARF6 regulates F-actin mobilization and GLUT4 glucose transporter translocation to the plasma membrane Molecular and Cellular Biology. 21: 5262-5275. PMID 11438680 DOI: 10.1128/Mcb.21.15.5262-5275.2001  0.737
2001 Mohr G, Rennard R, Cherniack AD, Stryker J, Lambowitz AM. Function of the Neurospora crassa mitochondrial tyrosyl-tRNA synthetase in RNA splicing. Role of the idiosyncratic N-terminal extension and different modes of interaction with different group I introns Journal of Molecular Biology. 307: 75-92. PMID 11243805 DOI: 10.1006/Jmbi.2000.4460  0.521
2000 Iwanishi M, Czech MP, Cherniack AD. The protein-tyrosine kinase Fer associates with signaling complexes containing insulin receptor substrate-1 and phosphatidylinositol 3-kinase Journal of Biological Chemistry. 275: 38995-39000. PMID 11006284 DOI: 10.1074/Jbc.M006665200  0.568
1996 Klarlund JK, Cherniack AD, McMahon M, Czech MP. Role of the Raf/mitogen-activated protein kinase pathway in p21(ras) desensitization Journal of Biological Chemistry. 271: 16674-16677. PMID 8663295 DOI: 10.1074/Jbc.271.28.16674  0.74
1995 Cherniack AD, Klarlund JK, Conway BR, Czech MP. Disassembly of Son-of-sevenless proteins from Grb2 during p21ras desensitization by insulin. The Journal of Biological Chemistry. 270: 1485-8. PMID 7829473 DOI: 10.1074/Jbc.270.4.1485  0.741
1995 Klarlund JK, Cherniack AD, Czech MP. Divergent mechanisms for homologous desensitization of p21ras by insulin and growth factors Journal of Biological Chemistry. 270: 23421-23428. PMID 7559502 DOI: 10.1074/Jbc.270.40.23421  0.741
1993 Baltensperger K, Kozma LM, Cherniack AD, Klarlund JK, Chawla A, Banerjee U, Czech MP. Binding of the Ras activator son of sevenless to insulin receptor substrate-1 signaling complexes. Science (New York, N.Y.). 260: 1950-2. PMID 8391166 DOI: 10.1126/Science.8391166  0.751
1992 Kämper U, Kück U, Cherniack AD, Lambowitz AM. The mitochondrial tyrosyl-tRNA synthetase of Podospora anserina is a bifunctional enzyme active in protein synthesis and RNA splicing Molecular and Cellular Biology. 12: 499-511. PMID 1531084 DOI: 10.1128/Mcb.12.2.499  0.493
1990 Cherniack AD, Garriga G, Kittle JD, Akins RA, Lambowitz AM. Function of Neurospora mitochondrial tyrosyl-tRNA synthetase in RNA splicing requires an idiosyncratic domain not found in other synthetases. Cell. 62: 745-55. PMID 2143700 DOI: 10.1016/0092-8674(90)90119-Y  0.543
Show low-probability matches.